As reported for isatuximab and daratumumab, mass spectrometry analyses and the use of specific IFE-reflex assays (i.e., isatuximab Hydrashift assay, DIRA assay) can overcome interference by these therapeutic antibodies and allow more accurate measurements of serum M-protein in MM patients [48, 53–55]. The gene discussed is MYOM2; the disease is Miyoshi myopathy.